Shandong Lukang Pharmaceutical Co Ltd

Lukang Pharmaceutical announced that the company has received the Drug Registration Certificate for Cefuroxime Sodium for Injection issued by the National Medical Products Administration, and the drug has been approved for registration. The drug is a Category 4 chemical medicine, with specifications including 0.75 grams and 1.5 grams. Cefuroxime is a cephalosporin antibiotic, and 46 domestic companies have currently passed consistency evaluation or obtained approval for generic drugs under the new registration classification. As of the disclosure date of the announcement, the company has invested approximately 2.79 million yuan in the research and development of this drug. The approval of this drug will enrich the company's formulation product line, but drug sales are subject to uncertainties due to factors such as policies and market conditions.

Lu Kang Pharmaceutical released its 2026 interim report. Total operating revenue was 3.238 billion yuan, up 2.66% year-on-year. Net profit attributable to the parent company was 138 million yuan, up 29.31% year-on-year. Net cash inflow from operating activities was 359 million yuan, up 14.88% year-on-year, marking a second consecutive year of growth. The company's asset-liability ratio was 45.18%, down 8.78 percentage points from the same period last year. Gross margin was 22.18%, up 0.86 percentage points from the previous quarter. Diluted earnings per share were 0.13 yuan, up 8.33% year-on-year.

Lukang Pharmaceutical announced that its controlling subsidiary Saite Company received the Drug Supplementary Application Approval Notice for Crisaborole Ointment issued by the National Medical Products Administration, approving Saite Company as the marketing authorization holder of the drug. The drug specification is 2 percent, 30 grams to 0.6 grams, indicated for topical treatment of mild to moderate atopic dermatitis in patients aged 3 months and older. The original drug was approved by the U.S. FDA in 2016. After the transfer, the production site, formulation, and manufacturing process remain consistent with the original drug, and the original drug approval number remains unchanged.